Arbutus Biopharma (ABUS) Return on Capital Employed (2010 - 2026)
Arbutus Biopharma recorded quarterly Return on Capital Employed of 86.54% in Q1 2026, up 304.46% quarter-over-quarter from 42.33% in Q4 2025, and up 16531.0% year-over-year from N/an in Q1 2025.
Arbutus Biopharma's Return on Capital Employed history runs 17 years deep, the most recent figure standing at 86.54% for Q1 2026.
- In Q1 2026, Return on Capital Employed rose 16531.0% year-over-year to 86.54%; the TTM figure through Mar 2026 stood at 86.54% (up 16531.0% YoY), while the FY2025 annual figure was 35.61%, up 2672.0% from the prior year.
- Return on Capital Employed came in at 86.54% for Q1 2026 at Arbutus Biopharma, up from 42.33% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 86.54% in Q1 2026 to a low of 78.77% in Q1 2025.
- A 5-year average of 43.66% and a median of 49.11% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed plunged 2128 bps in 2023 and surged 16531 bps in 2026, its largest moves.
- Arbutus Biopharma's Return on Capital Employed stood at 39.25% in 2022, then plunged by 54 bps to 60.53% in 2023, then decreased by 5 bps to 63.36% in 2024, then surged by 33 bps to 42.33% in 2025, then surged by 304 bps to 86.54% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 86.54%, 42.33%, and 49.11% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Arbutus Biopharma | 883.58 Mn | 883.58 Mn | - | 86.54% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 86.54% |
| Dec 31, 2025 | -42.33% |
| Sep 30, 2025 | -49.11% |
| Jun 30, 2025 | -56.68% |
| Mar 31, 2025 | -78.77% |
| Dec 31, 2024 | -63.36% |
| Sep 30, 2024 | -63.31% |
| Jun 30, 2024 | -62.80% |
| Mar 31, 2024 | -63.01% |
| Dec 31, 2023 | -60.53% |
| Sep 30, 2023 | -54.96% |
| Jun 30, 2023 | -47.76% |
| Mar 31, 2023 | -42.75% |
| Dec 31, 2022 | -39.25% |
| Sep 30, 2022 | -34.93% |
| Jun 30, 2022 | -32.71% |
| Mar 31, 2022 | -36.55% |
| Dec 31, 2021 | -42.30% |
| Sep 30, 2021 | -49.17% |
| Jun 30, 2021 | -49.89% |
| Mar 31, 2021 | -44.70% |
| Dec 31, 2020 | -46.41% |
| Sep 30, 2020 | -51.14% |
| Jun 30, 2020 | -139.03% |
| Mar 31, 2020 | -137.84% |
| Dec 31, 2019 | -138.98% |
| Sep 30, 2019 | -101.14% |
| Jun 30, 2019 | -46.42% |
| Mar 31, 2019 | -43.18% |
| Dec 31, 2018 | -39.83% |
| Sep 30, 2018 | -53.56% |
| Jun 30, 2018 | -43.36% |
| Mar 31, 2018 | -45.66% |
| Dec 31, 2017 | -49.55% |
| Sep 30, 2017 | -128.80% |
| Jun 30, 2017 | -125.82% |
| Mar 31, 2017 | -187.61% |
| Dec 31, 2016 | -127.78% |
| Sep 30, 2016 | -47.81% |
| Jun 30, 2016 | -46.97% |
| Mar 31, 2016 | -14.97% |
| Dec 31, 2015 | -14.48% |
| Sep 30, 2015 | -13.80% |
| Jun 30, 2015 | -6.54% |
| Mar 31, 2015 | -10.52% |
| Dec 31, 2014 | -32.51% |
| Sep 30, 2014 | -22.61% |
| Jun 30, 2014 | -18.03% |
| Mar 31, 2014 | -18.79% |
| Dec 31, 2013 | -27.89% |
| Sep 30, 2013 | -49.72% |
| Jun 30, 2013 | -37.74% |
| Mar 31, 2013 | -33.81% |
| Dec 31, 2012 | -63.00% |
| Sep 30, 2012 | -428.79% |
| Jun 30, 2012 | -143.01% |
| Mar 31, 2012 | -159.33% |
| Dec 31, 2011 | -135.49% |
| Sep 30, 2011 | -98.38% |
| Jun 30, 2011 | -115.49% |
| Mar 31, 2011 | -95.04% |
| Dec 31, 2010 | -61.17% |